{"name":"Beijing Minhai Biotechnology Co., Ltd","slug":"beijing-minhai-biotechnology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Act-HIB®","genericName":"Act-HIB®","slug":"act-hib","indication":"Prevention of invasive disease caused by Haemophilus influenzae type b in infants and children","status":"phase_3"},{"name":"Hib Vaccine Group","genericName":"Hib Vaccine Group","slug":"hib-vaccine-group","indication":"Prevention of invasive Haemophilus influenzae type b disease in infants and children","status":"phase_3"},{"name":"MCV-AC Vaccine Group","genericName":"MCV-AC Vaccine Group","slug":"mcv-ac-vaccine-group","indication":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A and C","status":"phase_3"},{"name":"MCV-ACYW135 Vaccine Group","genericName":"MCV-ACYW135 Vaccine Group","slug":"mcv-acyw135-vaccine-group","indication":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135","status":"phase_3"},{"name":"MPV-ACYW135 Vaccine Group","genericName":"MPV-ACYW135 Vaccine Group","slug":"mpv-acyw135-vaccine-group","indication":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135","status":"phase_3"},{"name":"Minhai-HIB","genericName":"Minhai-HIB","slug":"minhai-hib","indication":"Prevention of invasive Haemophilus influenzae type b disease in infants and children","status":"phase_3"},{"name":"sIPV+bOPV","genericName":"sIPV+bOPV","slug":"sipv-bopv","indication":"Prevention of poliomyelitis","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"MPV-A Vaccine Group","genericName":"MPV-A Vaccine Group","slug":"mpv-a-vaccine-group","indication":"Prevention of multiple viral infections (specific pathogens not publicly detailed)","status":"phase_3"},{"name":"wIPV","genericName":"wIPV","slug":"wipv","indication":"Treatment of COVID-19","status":"phase_3"},{"name":"wIPV+bOPV","genericName":"wIPV+bOPV","slug":"wipv-bopv","indication":"Prevention of COVID-19 caused by SARS-CoV-2","status":"phase_3"}]}],"pipeline":[{"name":"Act-HIB®","genericName":"Act-HIB®","slug":"act-hib","phase":"phase_3","mechanism":"Act-HIB is a conjugate vaccine that stimulates immune response against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier.","indications":["Prevention of invasive disease caused by Haemophilus influenzae type b in infants and children"],"catalyst":""},{"name":"Hib Vaccine Group","genericName":"Hib Vaccine Group","slug":"hib-vaccine-group","phase":"phase_3","mechanism":"Hib vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) bacteria, preventing infection.","indications":["Prevention of invasive Haemophilus influenzae type b disease in infants and children"],"catalyst":""},{"name":"MCV-AC Vaccine Group","genericName":"MCV-AC Vaccine Group","slug":"mcv-ac-vaccine-group","phase":"phase_3","mechanism":"MCV-AC is a meningococcal conjugate vaccine that stimulates immune responses against multiple serogroups of Neisseria meningitidis to prevent meningococcal disease.","indications":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A and C"],"catalyst":""},{"name":"MCV-ACYW135 Vaccine Group","genericName":"MCV-ACYW135 Vaccine Group","slug":"mcv-acyw135-vaccine-group","phase":"phase_3","mechanism":"MCV-ACYW135 is a meningococcal conjugate vaccine that stimulates immune response against serogroups A, C, Y, and W-135 of Neisseria meningitidis.","indications":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135"],"catalyst":""},{"name":"MPV-A Vaccine Group","genericName":"MPV-A Vaccine Group","slug":"mpv-a-vaccine-group","phase":"phase_3","mechanism":"MPV-A is a multi-pathogen vaccine designed to provide immunological protection against multiple viral pathogens through stimulation of adaptive immune responses.","indications":["Prevention of multiple viral infections (specific pathogens not publicly detailed)"],"catalyst":""},{"name":"MPV-ACYW135 Vaccine Group","genericName":"MPV-ACYW135 Vaccine Group","slug":"mpv-acyw135-vaccine-group","phase":"phase_3","mechanism":"MPV-ACYW135 is a meningococcal polysaccharide conjugate vaccine that stimulates immune responses against serogroups A, C, Y, and W-135 of Neisseria meningitidis.","indications":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135"],"catalyst":""},{"name":"Minhai-HIB","genericName":"Minhai-HIB","slug":"minhai-hib","phase":"phase_3","mechanism":"Minhai-HIB is a Haemophilus influenzae type b (Hib) conjugate vaccine that stimulates immune responses against the polysaccharide capsule of H. influenzae type b bacteria.","indications":["Prevention of invasive Haemophilus influenzae type b disease in infants and children"],"catalyst":""},{"name":"sIPV+bOPV","genericName":"sIPV+bOPV","slug":"sipv-bopv","phase":"phase_3","mechanism":"This vaccine combines inactivated poliovirus (sIPV) and oral poliovirus vaccine (bOPV) to provide immunity against poliomyelitis.","indications":["Prevention of poliomyelitis"],"catalyst":""},{"name":"wIPV","genericName":"wIPV","slug":"wipv","phase":"phase_3","mechanism":"WIPV is a small molecule targeting the SARS-CoV-2 main protease.","indications":["Treatment of COVID-19"],"catalyst":""},{"name":"wIPV+bOPV","genericName":"wIPV+bOPV","slug":"wipv-bopv","phase":"phase_3","mechanism":"WIPV+bOPV is a vaccine that targets the SARS-CoV-2 virus.","indications":["Prevention of COVID-19 caused by SARS-CoV-2"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPTm9CS3NIbEN3OXctYkY3cVB0UkRET185UDhiV1IwcUpYRkhFQWZEVG5oMlZvajlTLW8xNHlCYlpsZEtSRklGd25QUmFVQ2o5SDJiOTE3alRYcjBXLS15Q2RvQnFpS2hRVkdSLXd6ckdNMUJfQ2FiekE4TXJ6TVpXaGhNMWdEajhOX0lqak9LSXBXMWR4V1ZtZzlR?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Pneumococcal Vaccines Market Future Business Opportunities - openPR.com","headline":"Pneumococcal Vaccines Market Future Business Opportunities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9GckRRcEdocWxXTmZpdGdCRHh4QTE5bUZhN0wwa3VES0JfUlJmZ2l6SDVWQ1B5cUZDYndMWklKNUF5UHJ4N3ZDbnAtU2hXbDRkY0dZeUUtVHZSczdQdzFITXE1YzFKOG5Ec0JkeE9ySlhjUnkwaE5wYW5xajNQOHM?oc=5","date":"2025-07-10","type":"pipeline","source":"Insightace Analytic","summary":"Combination Vaccines Market Scope, Size, Share and Forecast to 2031 - Insightace Analytic","headline":"Combination Vaccines Market Scope, Size, Share and Forecast to 2031","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNa3JkVzFEaU1YYV9RMUZ4U0JQQXNic3FBdHpPYTY2bTZQV3MtOEdNQ0ZGRjJMQVlrZjJEdFh4Q0VLYnZBVHdFWlBGS3RrSy1FRUtTZmI0N2xDUUd6SmZMTFltbmVzZXhaWmtsRzBpemNxQUtrYS05RkhETkp1Tmo1VUw4bmw0YXRwdjdKR0pOMzd4b2hwZDRqWFdTaW9MWWc?oc=5","date":"2024-10-04","type":"pipeline","source":"Frontiers","summary":"Optimization of manufacturing process for serotype 14 pneumococcal capsular polysaccharide - Frontiers","headline":"Optimization of manufacturing process for serotype 14 pneumococcal capsular polysaccharide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxORmYtalZlX21OeUhVZnBlTTRjM2NaQ3dIaEdOSmw3bmdOa080WGdNbi1Nd2d3SnBUS0ZvNURUU29ISnRHalhaeWJaVm91ajlpbGNwWGtIWGJKMlpONGNBa3hqN0FhOWQ0eldHUWVNQVMzZUF2Sm0wN2FzdkRncDV5Z1k0QUpNZGVtYzR3?oc=5","date":"2024-08-27","type":"pipeline","source":"Grand View Research","summary":"India Pneumococcal Vaccine Market Size & Outlook, 2023-2030 - Grand View Research","headline":"India Pneumococcal Vaccine Market Size & Outlook, 2023-2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQbFd3ek43UC00QmNUdEZsazgxS2VTNGdHVVNwb3k1X3JQSTI1WG1EU2dNOTBYVFZoTTV0akIyUzV2QVVIUTZzbEgwZF95ei0tOG9wdXF1cDJhcHJhS3BRdktzWkFVcUx0LUs0QWFrSU9YX3BJOTI5Vlg3X3VUeFBEN1dEZDNOYjgxSGZZVGJjaDhMTUlYNUxucF9iVWgwaEZpSUc1RU5OUHk2eF9rQ2s0?oc=5","date":"2024-08-06","type":"pipeline","source":"Frontiers","summary":"Novel manufacturing process of pneumococcal capsular polysaccharides using advanced sterilization methods - Frontiers","headline":"Novel manufacturing process of pneumococcal capsular polysaccharides using advanced sterilization methods","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPUVFESzJPR3ZzUW93WEVZUm1lRVlfT2ZiaVpQdVRfSVkxbF9FQWNCRjFNV0Vqc1JCUDYycllzdWxrbmNIOVlveHM1LU5pWDkwd0JHcDVlczR2WDFhZ1QzSVhWRVFXVTQ5bHJDY0Z5cW5IQ3VoNDJxWXA4cUdweDJzbGhEdEl0cXBPd25NdFFiejdOVFQwaHBrWXRtbUxIdw?oc=5","date":"2023-10-04","type":"pipeline","source":"openPR.com","summary":"Hepatitis B Vaccine Market Opportunity Potential to Estimated CAGR 5.5% Driving Growth - openPR.com","headline":"Hepatitis B Vaccine Market Opportunity Potential to Estimated CAGR 5.5% Driving Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPdk9PTXBraHdsbjVnVkRMZnNLQUVUYTFxdmU5WFdSb3l3NTRWUHN1b0RjNW9YUzZHXzF4cWZsZU1QV2ZBZHFPTmtTQnRSbExGYmx6Nk5mTmNwUVJHejQ5Q2hPSm05Q3VFU2JvcjhTcFVZMU1sVzEzQ1JxNGl4Y2ZFWEhhcjZ1ZFNGNXBQRzFET1lTa0w4b3dLY1gtS1dBVk9ZYldKMUJNVUlDZHZuNE1kUGpzMTU0eTMwVm1ydUl6TQ?oc=5","date":"2023-04-07","type":"pipeline","source":"PR Newswire","summary":"Cooperation Agreement Concluded between BioKangtai and Biotis - PR Newswire","headline":"Cooperation Agreement Concluded between BioKangtai and Biotis","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_3":10},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}